Prostate cancer is the second most common cancer in men worldwide and the second leading cause of cancer deaths in men in the United States. Obesity has been consistently associated with lower 25-hydroxyvitamin D (25(OH)D) concentrations. Objectives: This cross-sectional study aimed to evaluate the serum vitamin D and PSA levels in Sudanese Obese and Non-Obese prostate cancer (PCa) attending the National Cancer Institute. Patients and Methods: Eighty six prostate cancer patients were included

more »

... this study, they were identified by clinical examination, histopathology and prostate-specific antigen (PSA). The mean age of them was 71.78 ± 8.04 years. Serum Vitamin D and PSA were measured by Electrochemiluminescence (ECL) immunoassay reactions using (Cobase411, serial No: 0868-16, manufactured by Hitachi high technologies corporation, Tokyo-Japan) the Elecsys reagents kit (Roche – Germany) Results: The means of serum vitamin D levels of among obese was 35.5 ± 15.4 ng/dL and 38.4 ± 16.2 ng/dL among non-obese group with non-significant differences(P=0.505). No significant association was observed between PSA levels and obese and non-obese (P=0.351). Vitamin D levels non-significantly negative correlated with BMI (r = -0.031, P = 0.778) and PSA (r = -0.062, P = 0.569), but there was insignificantly Positive correlated between PSA and vitamin D level (r = 0.151, P = 0.164). Conclusion: insignificant differences between vitamin D and serum PSA with BMI, Oral supplementation is recommended for individuals with low level of vitamin D. Keywords: Prostate cancer, Body mass index, Vitamin D, PSA, Sudanese.